For patients with inherited BM failure (BMF) or those with acquired BMF who fail immunosuppressive therapy and who lack a suitable alternative donor, the prognosis remains poor. Umbilical cord blood transplantation has extended the availability of hematopoietic stem cell transplantation in the absence of a suitable donor. A recent EBMT study confirmed the feasibility of this treatment and highlighted the fundamental role of the TNC dose (43.9 Â 10 7 /kg TNC/kg) on both engraftment and OS using cord blood as stem cell source in severe aplastic anemia. However, this procedure is still experimental and should be evaluated only through prospective clinical trials. (2013) 48, 201-202; doi:10.1038/bmt.2012.252; published online 7 January 2013
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For patients with inherited BM failure (BMF) or those with acquired BMF who fail immunosuppressive therapy and who lack a suitable alternative donor, the prognosis remains poor. Umbilical cord blood transplantation has extended the availability of hematopoietic stem cell transplantation in the absence of a suitable donor. A recent EBMT study confirmed the feasibility of this treatment and highlighted the fundamental role of the TNC dose (43.9 Â 10 7 /kg TNC/kg) on both engraftment and OS using cord blood as stem cell source in severe aplastic anemia. However, this procedure is still experimental and should be evaluated only through prospective clinical trials. Keywords: cord blood; transplantation; aplastic anemia CORD BLOOD TRANSPLANTATION APLASTIC ANEMIA Acquired bone marrow failure (BMF) syndromes, such as severe aplastic anemia (SAA) or inherited Fanconi anemia, are rare diseases. The outcome of these patients has greatly improved over time, but is still poor for patients who lack a sibling donor and who failed or relapsed after immunosuppressive therapy (IST). Use of alternative donors has been historically associated with poor long-term survival. [1] [2] [3] However, recently, transplantation from unrelated donors has improved significantly because of better HLA matching, optimization of the conditioning regimen and improvement in supportive care. [4] [5] [6] For patients with inherited BMF or those with acquired BMF who fail IST and who lack a suitable alternative donor, the prognosis remains, however, extremely poor. Umbilical cord blood transplantation (UCBT) has extended the availability of hematopoietic SCT in the absence of a suitable donor. To date, double UCBT has been reported in only few patients with BMF.
We evaluated this procedure in 14 patients (8 Fanconi anemia, 5 SAA and 1 paroxysmal nocturnal hemoglobinuria (PNH)) who received double cord blood transplantation (dUCBT) from 2004 to 2007 in Saint Louis Hospital in Paris, France. 7 With a median follow-up of 23 months, the estimated 2 year OS rates were 80±17% and 33±16% for patients with acquired and inherited BMF syndromes, respectively. Transplantation of two partially HLAmatched UCB thus enabled salvage treatment of high-risk patients with BMF syndromes. However, as dUCBT is associated with high incidence of GVHD, in spite of our limited experience, when possible, we have recommended the use of only one cord blood unit with high number of cells and not more than 1 out of 6 HLA mismatch in patients with Fanconi Anemia. 8 Results of single unit UCBT for patients with Fanconi anemia have been reported. OS was 40 ± 5% and factors associated with favorable outcome were use of fludarabine in the conditioning regimen, number of nucleated cells infused X4.9 Â 10 7 /kg, and negative CMV serology in the recipient. 2 Regarding results of UCBT in patients with acquired SAA, we have reported an analysis on 71 patients (33 males) diagnosed with SAA, (9 with PNH) who received a single UCBT (n ¼ 57, 79%) or double UCBT (n ¼ 14, 19%) between January 1996 and January 2009 in 32 centers (23 EBMT centers). 9 The median age was 13 years (range 2-68 years; 28 adults). Fortysix patients (69%) received reduced intensity conditioning regimens, most of which were fludarabine-based. GVHD prophylaxis consisted mainly of CYA and steroids (70% of patients). Cumulative incidence (CI) of neutrophil recovery (4500 mm 3 ) at day 60 was 51 ± 6% with a median time of 25 days (6-91). In multivariate analysis, the only factor associated with shorter time to engraftment and higher probability of engraftment was the pre-freezing TNC dose (43.9 Â 10 7 /kg, hazard ratio: 1.5, 95% confidence interval: 1-2.2, P ¼ 0.05). Chimerism analysis for patients who engrafted (n ¼ 37) showed full donor chimerism in 82%. The CI of grade II-IV acute GVHD was 20±5% (10 grade II, 5 grade III, 2 grade IV). Eleven patients out of 34 at risk developed chronic GVHD with 3 years CI of 18 ± 5%. With a median follow-up of 35 months (3-83), the estimated probability of 3 years OS was 38 ± 6%. The main cause of death was graft failure associated with infections (n ¼ 14, 32%). In multivariate analysis, the only factor associated with survival was pre-freezing TNC dose (43.9 Â 10 7 / Kg RR: 0.4, 95% confidence interval: 0.2-0.8, P ¼ 0.007). In conclusion, this study highlights the fundamental role of the TNC dose (43.9 Â 107/kg TNC/kg) on both engraftment and OS using cord blood as stem cell source in SAA.
EBMT RECOMMENDATIONS
The Apcord Protocol (on behalf of the French Society for Stem Cell Transplantation and Eurocord-EBMT Study on Cord Blood Transplantation in Severe Aplastic Anemia-APCORD Protocol).
A Prospective Phase II Study was initiated to evaluate cord blood transplantation in inherited or acquired SAA refractory or in relapse after IST. This protocol concerns all inherited or acquired BMF in relapse after IST in the absence of an HLA matched (related or unrelated) donor. The main objective is OS at 1 year (efficacy X50% and rejection rate p20%). Inclusion criteria are: age: 3-55 years, inherited aplastic anemia (with SAA criteria) or acquired aplastic anemia in relapse or treatment failure after IST without clonal evolution, and Karnofsky Index X60%. One or 2 cord blood units containing alone or both together more than 4 Â 10 7 frozen nucleated cells/Kg with no more than 2 out of 6 HLA mismatches between the units and the patient, for cases of acquired SAA are recommended. The use of one cord blood unit is possible if the compatibility and the cell dose are respected. Concerning inherited BMF, only one cord blood unit is acceptable with no more than one mismatch. Twenty-six patients will be included. The conditioning regimen consists of fludarabine 30 mg/m 2 from D-6 to D-3, CY 30 mg/kg from D-6 to D-3 (10 mg/Kg/day for patients with Fanconi Anemia), ATG (thymoglobulin) 2.5 mg/kg from D-3 to D-2, TBI (2 Gray) on D-2. One injection of anti-CD20 150 mg/m 2 is recommended at day þ 5 to prevent EBV reactivation. CYA is given alone as GVHD prophylaxis.
